Quantum biopharma's 2024 financial statements show strong improvements in cash, working capital, operating efficiency and the removal of material uncertainty related to going concern

Completion of unbuzzdtm clinical trial and multiple sclerosis drug lucid-21-302 phase 1 trial advance company's pipeline of products and assets toronto, ontario / access newswire / march 28, 2025 / quantum biopharma ltd. (nasdaq:qntm)(cse:qntm)(fra:0k91) ("quantum biopharma" or the "company"),has reported its financial and operational results for the fourth quarter and year ended december 31, 2024.
QNTM Ratings Summary
QNTM Quant Ranking